Neuroendocrine tumors of the pancreas

Oncologist

Volumn 14, Issue 5, 2009, Pages 456-467

  Ehehalt, Florian ^a   Saeger, Hans D ^a   Schmidt, C Max ^b   Grützmann, Robert ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gastrinoma; Insulinoma; Neuroendocrine; Pancreas; Tumor

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN;

ACTH SECRETING ADENOMA; ADENOCARCINOMA; ADVANCED CANCER; ANGIOGRAPHY; ANTIANGIOGENIC THERAPY; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GRADING; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CARCINOID; CHEMOEMBOLIZATION; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CRYOTHERAPY; CYTOREDUCTIVE SURGERY; DECISION MAKING; DIET THERAPY; ENDOSCOPIC ECHOGRAPHY; GASTRINOMA; GLUCAGONOMA; HISTOPATHOLOGY; HUMAN; HYPOGLYCEMIA; INSULINOMA; LIVER METASTASIS; LOW LEVEL LASER THERAPY; LYMPHADENECTOMY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CARCINOMA; PANCREAS RESECTION; PANCREAS SURGERY; PANCREAS TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PATHOGENESIS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; RADIOISOTOPE THERAPY; REVIEW; RISK ASSESSMENT; SCINTIGRAPHY; SOMATOSTATINOMA; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; ULTRASOUND; VIPOMA;

GASTRINOMA; HUMANS; INCIDENCE; INSULINOMA; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 66349128030     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0259     Document Type: Review

References (130)

1. Quaedvlieg PF, Visser O, Lamers CB et al. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol 2001;12:1295-1300. (Pubitemid 32994760)
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-959. (Pubitemid 36173145)
3. Lepage C, Bouvier AM, Phelip JM et al. Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 2004;53:549-553. (Pubitemid 38372980)
4. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden. Cancer 2001;92:2204-2210.
5. Rindi G, Leiter AB, Kopin AS et al. The "normal" endocrine cell of the gut: Changing concepts and new evidences. Ann N Y Acad Sci 2004;1014:1-12.
6. Thompson JC, Townsend CM. Endocrine pancreas. In: Townsend CM, Beauchamp RD, Evers BM et al., eds. Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice. Philadelphia: Elsevier Saunders, 2004:1001-1021.
7. Panzuto F, Nasoni S, Falconi M et al. Prognostic factors and survival in endocrine tumor patients: Comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083-1092. (Pubitemid 41815799)
8. Terris B, Meddeb M, Marchio A et al. Comparative genomic hybridization analysis of sporadic neuroendocrine tumors of the digestive system. Genes Chromosomes Cancer 1998;22:50-56. (Pubitemid 28217806)
9. Zikusoka MN, Kidd M, Eick G et al. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 2005;104:2292-2309. (Pubitemid 41691550)
10. Moldow RE, Connelly RR. Epidemiology of pancreatic cancer in Connecticut. Gastroenterology 1968;55:677-686.
11. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005;19:753-781. (Pubitemid 41614122)
12. Yao JC, Eisner MP, Leary C et al. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007;14:3492-3500. (Pubitemid 350160130)
13. Fesinmeyer MD, Austin MA, Li CI et al. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1766-1773. (Pubitemid 40995093)
14. Bilimoria KY, Bentrem DJ, Merkow RP et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007;205:558-563. (Pubitemid 47446316)
15. Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res 2004;120:139-161. (Pubitemid 38686540)
16. Buchanan KD, Johnston CF, O'Hare MM et al. Neuroendocrine tumors. A European view. Am J Med 1986;81:14-22.
17. Eriksson B, Oberg K, Skogseid B. Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients. Acta Oncol 1989;28:373-377.
18. Watson RG, Johnston CF, O'Hare MM et al. The frequency of gastrointestinal endocrine tumours in a well-defined population-Northern Ireland 1970-1985. Q J Med 1989;72:647-657.
19. Lam KY, Lo CY. Pancreatic endocrine tumour: A 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature. Eur J Surg Oncol 1997;23:36-42. (Pubitemid 27107490)
20. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995;75(1 suppl):171-190.
21. Halfdanarson TR, Rabe KG, Rubin J et al. Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;19:1727-1733.
22. Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci 1991;36:933-942.
23. Bruzoni M, Johnston E, Sasson AR. Pancreatic incidentalomas: Clinical and pathologic spectrum. Am J Surg 2008;195:329-332; discussion 332.
24. Fendrich V, Waldmann J, Bartsch DK et al. Multiple primary malignancies in patients with sporadic pancreatic endocrine tumors. J Surg Oncol 2008;97:592-595.
25. Halfdanarson TR, Rubin J, Farnell MB et al. Pancreatic endocrine neoplasms: Epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer 2008;15:409-427.
26. Pape UF, Böhmig M, Berndt U et al. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center. Ann N Y Acad Sci 2004;1014:222-233. (Pubitemid 38594810)
27. Broder LE, Carter SK. Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann Intern Med 1973;79:101-107.
28. Broughan TA, Leslie JD, Soto JM et al. Pancreatic islet cell tumors. Surgery 1986;99:671-678. (Pubitemid 16069108)
29. Dial PF, Braasch JW, Rossi RL et al. Management of nonfunctioning islet cell tumors of the pancreas. Surg Clin North Am 1985;65:291-299. (Pubitemid 15246022)
30. Grama D, Skogseid B, Wilander E et al. Pancreatic tumors in multiple endocrine neoplasia type 1: Clinical presentation and surgical treatment. World J Surg 1992;16:611-618; discussion 618-619.
31. Klöppel G, Heitz PU. Pancreatic endocrine tumors. Pathol Res Pract 1988;183:155-168. (Pubitemid 18119318)
32. Legaspi A, Brennan MF. Management of islet cell carcinoma. Surgery 1988;104:1018-1023. (Pubitemid 19011981)
33. Marion-Audibert AM, Barel C, Gouysse G et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 2003;125:1094-1104. (Pubitemid 37193456)
34. Couvelard A, O'Toole D, Turley H et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: Negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 2005;92:94-101. (Pubitemid 40188441)
35. Falconi M, Plockinger U, Kwekkeboom DJ et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006;84:196-211. (Pubitemid 46361054)
36. Wiedenmann B, Franke WW, Kuhn C et al. Synaptophysin:Amarker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci U S A 1986;83:3500-3504. (Pubitemid 16051994)
37. Tapia FJ, Polak JM, Barbosa AJ et al. Neuron-specific enolase is produced by neuroendocrine tumours. Lancet 1981;1:808-811. (Pubitemid 11147436)
38. Wilson BS, Lloyd RV. Detection of chromogranin in neuroendocrine cells with a monoclonal antibody. Am J Pathol 1984;115:458-468. (Pubitemid 14121197)
39. Brissova M, Fowler MJ, Nicholson WE et al. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem 2005;53:1087-1097. (Pubitemid 41262977)
40. Soga J, Yakuwa Y. Vipoma/diarrheogenic syndrome: A statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 1998;17:389-400. (Pubitemid 29083408)
41. Mallinson CN, Bloom SR, Warin AP et al. A glucagonoma syndrome. Lancet 1974;2:1-5.
42. Garbrecht N, Anlauf M, Schmitt A et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: Incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 2008;15:229-241.
43. Kuo SC, Gananadha S, Scarlett CJ et al. Sporadic pancreatic polypeptide secreting tumors (PPomas) of the pancreas. World J Surg 2008;32:1815-1822.
44. Soga J. Carcinoids of the pancreas: An analysis of 156 cases. Cancer 2005;104:1180-1187. (Pubitemid 41278952)
45. Chastain MA. The glucagonoma syndrome: A review of its features and discussion of new perspectives. Am J Med Sci 2001;321:306-320. (Pubitemid 32428831)
46. O'Toole D, Salazar R, Falconi M et al. Rare functioning pancreatic endocrine tumors. Neuroendocrinology 2006;84:189-195. (Pubitemid 46361053)
47. Srirajaskanthan R, McStay M, Toumpanakis C et al. Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: Case series and literature review. Neuroendocrinology 2009;84:48-55.
48. Volante M, Righi L, Asioli S et al. Goblet cell carcinoids and other mixed neuroendocrine/nonneuroendocrine neoplasms. Virchows Arch 2007;451(suppl 1):S61-S69. (Pubitemid 47283379)
49. Levine F, Itkin-Ansari P. beta-cell regeneration: Neogenesis, replication or both? J Mol Med 2008;86:247-258.
50. Vortmeyer AO, Huang S, Lubensky I et al. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab 2004;89:1934-1938. (Pubitemid 38507955)
51. Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-407. (Pubitemid 27180699)
52. Lemmens I, Van de Ven WJ, Kas K et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 1997;6:1177-1183. (Pubitemid 27308405)
53. Leotlela PD, Jauch A, Holtgreve-Grez H et al. Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 2003;10:437-450. (Pubitemid 38094880)
54. Yang Y, Hua X. In search of tumor suppressing functions of menin. Mol Cell Endocrinol 2007;265-266:34-41.
55. Akerström G, Hessman O, Hellman P et al. Pancreatic tumours as part of the MEN-1 syndrome. Best Pract Res Clin Gastroenterol 2005;19:819-830. (Pubitemid 41614126)
56. Dean PG, van Heerden JA, Farley DR et al. Are patients with multiple endocrine neoplasia type I prone to premature death? World J Surg 2000;24:1437-1441.
57. Jensen RT, Niederle B, Mitry E et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006;84:173-182. (Pubitemid 46361051)
58. Toumpanakis CG, Caplin ME. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Am J Gastroenterol 2008;103:729-732.
59. Akerström G, Hessman O, Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbecks Arch Surg 2002;386:558-569. (Pubitemid 34285635)
60. Lott ST, Chandler DS, Curley SA et al. High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumors: Evidence for a stepwise mechanism for malignant conversion in VHL tumorigenesis. Cancer Res 2002;62:1952-1955. (Pubitemid 34408436)
61. Hammel PR, Vilgrain V, Terris B et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000;119:1087-1095.
62. Lubensky IA, Pack S, Ault D et al. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: Histopathological and molecular genetic analysis. Am J Pathol 1998;153:223-231. (Pubitemid 28317525)
63. Francalanci P, Diomedi-Camassei F, Purificato C et al. Malignant pancreatic endocrine tumor in a child with tuberous sclerosis. Am J Surg Pathol 2003;27:1386-1389. (Pubitemid 37185831)
64. Eledrisi MS, Stuart CA, Alshanti M. Insulinoma in a patient with tuberous sclerosis: Is there an association? Endocr Pract 2002;8:109-112.
65. Verhoef S, van Diemen-Steenvoorde R, Akkersdijk WL et al. Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. Eur J Pediatr 1999;158:284-287. (Pubitemid 29183702)
66. Cappelli C, Agosti B, Braga M et al. Von Recklinghausen's neurofibromatosis associated with duodenal somatostatinoma. A case report and review of the literature. Minerva Endocrinol 2004;29:19-24.
67. Tan CC, Hall RI, Semeraro D et al. Ampullary somatostatinoma associated with von Recklinghausen's neurofibromatosis presenting as obstructive jaundice. Eur J Surg Oncol 1996;22:298-301. (Pubitemid 26229684)
68. Duerr EM, Chung DC. Molecular genetics of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab 2007;21:1-14. (Pubitemid 46436730)
69. Duerr EM, Mizukami Y, Ng A et al. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer 2008;15:243-256.
70. Rindi G, Bordi C. Endocrine tumours of the gastrointestinal tract: Aetiology, molecular pathogenesis and genetics. Best Pract Res Clin Gastroenterol 2005;19:519-534.
71. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: The WHO classification. Ann N Y Acad Sci 2004;1014:13-27. (Pubitemid 38594787)
72. Solcia E, Klöppel G, Sobin LH. Histological typing of endocrine tumours., in World Health Organization International Classification of Tumours. 2000, Springer: Berlin.61-68.
73. Heitz PU, Komminoth P, Perrin A et al. Pancreatic endocrine tumors: Introduction. In: DeLellis DA, Lloyd RV, Heitz PU et al., eds. Pathology and Genetics of Tumours of Endocrine Organs. WHO Classification of Tumours. Lyon, France: IARC Press, 2004:177-182.
74. Capella C, Heitz PU, Höfler H et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995;425:547-560.
75. Schindl M, Kaczirek K, Kaserer K et al. Is the new classification of neuroendocrine pancreatic tumors of clinical help? World J Surg 2000;24:1312-1318.
76. Hochwald SN, Zee S, Conlon KC et al. Prognostic factors in pancreatic endocrine neoplasms: An analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20:2633-2642. (Pubitemid 34575635)
77. Pape UF, Berndt U, Müller-Nordhorn J et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008;15:1083-1097.
78. Van Eeden S, Quaedvlieg PF, Taal BG et al. Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol 2002;33:1126-1132. (Pubitemid 35416711)
79. Artale S, Giannetta L, Cerea G et al. Treatment of metastatic neuroendocrine carcinomas based on WHO classification. Anticancer Res 2005;25:4463-4469. (Pubitemid 41729497)
80. Bajetta E, Catena L, Procopio G et al. Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann Oncol 2005;16:1374-1380.
81. Rindi G, Klöppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch 2006;449:395-401. (Pubitemid 44451313)
82. Pape UF, Jann H, Ml̈ler-Nordhorn J et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008;113:256-265.
83. Bilimoria KY, Talamonti MS, Tomlinson JS et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: Analysis of 3851 patients. Ann Surg 2008;247:490-500.
84. Schurr PG, Strate T, Rese K et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: An institutional experience. Ann Surg 2007;245:273-281. (Pubitemid 46148487)
85. Modlin IM, Moss SF, Chung DC et al. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 2008;100:1282-1289.
86. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol 2005;19:783-798.
87. Service FJ, McMahon MM, O'Brien PC et al. Functioning insulinoma - incidence, recurrence, and long-term survival of patients: A 60-year study. Mayo Clin Proc 1991;66:711-719.
88. Norton JA, Fraker DL, Alexander HR et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999;341:635-644. (Pubitemid 29399042)
89. Fendrich V, Langer P, Celik I et al. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg 2006;244:845-851; discussion 852-853. (Pubitemid 44808610)
90. de Herder WW, Niederle B, Scoazec JY et al. Well-differentiated pancreatic tumor/carcinoma: Insulinoma. Neuroendocrinology 2006;84:183-188. (Pubitemid 46361052)
91. Nilsson O, Van Cutsem E, Delle Fave G et al. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 2006;84:212-215. (Pubitemid 46361055)
92. Kenney B, Tormey CA, Qin L et al. Adult nesidioblastosis. Clinicopathologic correlation between pre-operative selective arterial calcium stimulation studies and post-operative pathologic findings. JOP 2008;9:504-511.
93. Starke A, Saddig C, Kirch B et al. Islet hyperplasia in adults: Challenge to preoperatively diagnose non-insulinoma pancreatogenic hypoglycemia syndrome. World J Surg 2006;30:670-679. (Pubitemid 43724093)
94. Anlauf M, Wieben D, Perren A et al. Persistent hyperinsulinemic hypoglycemia in 15 adults with diffuse nesidioblastosis: Diagnostic criteria, incidence, and characterization of beta-cell changes. Am J Surg Pathol 2005;29:524-533. (Pubitemid 40411187)
95. Rickes S, Rauh P, Uhle C et al. Contrast-enhanced sonography in pancreatic diseases. Eur J Radiol 2007;64:183-188. (Pubitemid 47588754)
96. Dörffel Y, Wermke W. Neuroendocrine tumors: Characterization with contrast-enhanced ultrasonography. Ultraschall Med 2008;29:506-514.
97. Vezzosi D, Bennet A, Rochaix P et al. Octreotide in insulinoma patients: Efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 2005;152:757-767. (Pubitemid 40744545)
98. Jackson JE. Angiography and arterial stimulation venous sampling in the localization of pancreatic neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2005;19:229-239. (Pubitemid 40347813)
99. Hashimoto LA, Walsh RM. Preoperative localization of insulinomas is not necessary. J Am Coll Surg 1999;189:368-373. (Pubitemid 29455676)
100. Fernández-Cruz L, Blanco L, Cosa R et al. Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg 2008;32:904-917.
101. Willberg B, Ml̈ler E. Surgery for nesidioblastosis - indications, treatment and results. Prog Pediatr Surg 1991;26:76-83.
102. Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 2000;62(suppl 1):73-78. (Pubitemid 30665943)
103. Roy PK, Venzon DJ, Shojamanesh H et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) 2000;79:379-411.
104. Howard TJ, Stabile BE, Zinner MJ et al. Anatomic distribution of pancreatic endocrine tumors. Am J Surg 1990;159:258-264. (Pubitemid 20057932)
105. Pascher A, Klupp J, Neuhaus P. Endocrine tumours of the gastrointestinal tract. Transplantation in the management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005;19:637-648.
106. Bartsch DK, Fendrich V, Langer P et al. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 2005;242:757-764; discussion 764-766. (Pubitemid 41714054)
107. Imamura M, Komoto I, Doi R et al. New pancreas-preserving total duodenectomy technique. World J Surg 2005;29:203-207. (Pubitemid 40576470)
108. Norton JA, Sugarbaker PH, Doppman JL et al. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg 1986;203:352-359. (Pubitemid 16056755)
109. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003;12:231-242. (Pubitemid 36210867)
110. Arnold R, Rinke A, Schmidt Ch et al. Endocrine tumours of the gastrointestinal tract: Chemotherapy. Best Pract Res Clin Gastroenterol 2005;19:649-656.
111. Creutzfeldt W, Bartsch HH, Jacubaschke U et al. Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide. Acta Oncol 1991;30:529-535.
112. Lowney JK, Frisella MM, Lairmore TC et al. Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: Correlation with primary tumor size. Surgery 1998;124:1043-1048; discussion 1048-1049. (Pubitemid 28555191)
113. Chamberlain RS, Canes D, Brown KT et al. Hepatic neuroendocrine metastases: Does intervention alter outcomes? J Am Coll Surg 2000;190:432-445.
114. Chen H, Hardacre JM, Uzar A et al. Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival? J Am Coll Surg 1998;187:88-92; discussion 92-93.
115. Khodjibekova M, Szyszko T, Singh A et al. Treatment of primary and secondary liver tumours with selective internal radiation therapy. J Exp Clin Cancer Res 2007;26:561-570.
116. Oyen WJ, Bodei L, Giammarile F et al. Targeted therapy in nuclear medicine - current status and future prospects. Ann Oncol 2007;18:1782-1792. (Pubitemid 350111565)
117. Kulke MH, Lenz HJ, Meropol NJ et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-3410.
118. Adler JT, Hottinger DG, Kunnimalaiyaan M et al. Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery 2008;144:956-961; discussion 961-962.
119. Yao JC, Phan AT, Chang DZ et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol 2008;26:4311-4318.
120. Ning L, Greenblatt DY, Kunnimalaiyaan M et al. Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells. The Oncologist 2008;13:98-104.
121. Moertel CG, Kvols LK, O'Connell MJ et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-232.
122. Jensen RT. Pancreatic endocrine tumors: Recent advances. Ann Oncol 1999;10(suppl 4):170-176. (Pubitemid 29333425)
123. Bilimoria KY, Tomlinson JS, Merkow RP et al. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: Analysis of 9,821 patients. J Gastrointest Surg 2007;11:1460-1467; discussion 1467-1469.
124. Thomas-Marques L, Murat A, Delemer B et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 2006;101:266-273. (Pubitemid 43381666)
125. Whipple AO. The surgical therapy of hyperinsulinism. J Int Chir 1938;3:237-276.
126. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955;142:709-723; discussion 724-728.
127. Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 1958;25:374-380.
128. Becker SW, Khan D, Rothman S. Cutaneous manifestations of internal malignant tumours. Arch Dermatol Syphilol 1942;45:1069-1080.
129. Larsson LI, Hirsch MA, Holst JJ et al. Pancreatic somatostatinoma. Clinical features and physiological implications. Lancet 1977;1:666-668.
130. Thorson A, Biorck G, Bjorkman G et al. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am Heart J 1954;47:795-817.